Search

Roche Holding AG

Atvērts

SektorsVeselības aprūpe

278.2 1.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

272.4

Max

279.4

Galvenie mērījumi

By Trading Economics

Ienākumi

6.3B

Pārdošana

31B

P/E

Sektora vidējais

26.169

57.333

Dividenžu ienesīgums

3.6

Peļņas marža

20.347

Darbinieki

103,249

EBITDA

11B

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.60%

2.63%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

205B

Iepriekšējā atvēršanas cena

276.82

Iepriekšējā slēgšanas cena

278.2

Roche Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 07:30 UTC

Peļņas

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

2025. g. 24. apr. 05:31 UTC

Peļņas

Roche Sales Rise Boosted By Key Drugs

2025. g. 9. apr. 09:39 UTC

Galvenie tirgus virzītāji

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025. g. 12. marts 09:23 UTC

Galvenie tirgus virzītāji

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

2025. g. 30. janv. 09:36 UTC

Peļņas

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

2025. g. 30. janv. 06:32 UTC

Peļņas

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

2025. g. 24. apr. 09:39 UTC

Tirgus saruna
Peļņas

Roche's Pipeline in Focus After Solid Results -- Market Talk

2025. g. 24. apr. 09:24 UTC

Tirgus saruna
Peļņas

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

2025. g. 24. apr. 09:18 UTC

Tirgus saruna
Peļņas

Roche's Results Are Solid -- Market Talk

2025. g. 24. apr. 05:16 UTC

Top Ziņas

Roche Sales Rise, Boosted By Key Drugs

2025. g. 22. apr. 10:51 UTC

Top Ziņas

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

2025. g. 15. apr. 09:55 UTC

Tirgus saruna

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2025. g. 9. apr. 10:03 UTC

Tirgus saruna
Peļņas

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

2025. g. 9. apr. 07:23 UTC

Tirgus saruna

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

2025. g. 3. apr. 08:41 UTC

Tirgus saruna

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

2025. g. 3. apr. 07:51 UTC

Tirgus saruna

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2025. g. 31. marts 09:31 UTC

Karstas akcijas

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

2025. g. 13. marts 07:46 UTC

Tirgus saruna

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

2025. g. 12. marts 16:34 UTC

Top Ziņas

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

2025. g. 12. marts 08:51 UTC

Tirgus saruna

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

2025. g. 12. marts 08:18 UTC

Tirgus saruna

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

2025. g. 13. febr. 11:43 UTC

Tirgus saruna

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

2025. g. 30. janv. 07:56 UTC

Tirgus saruna
Peļņas

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Issues 2025 View

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche Raises Dividend to CHF9.70 Vs CHF9.60

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche 2024 Core Operating Profit CHF20.82B

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche 2024 Net Pft CHF9.19B

2025. g. 30. janv. 06:02 UTC

Peļņas

Analysts Saw 2024 Core EPS at CHF18.59

Roche Holding AG Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.